Growing Geriatric Population Susceptible to Cardiovascular Diseases Fuels Unfractionated Heparin Market

With the presence of a copious number of large global players, the global unfractionated heparin market is marked by a highly consolidated vendor landscape. Large players are focused on mergers and strategic collaborations with small players to establish a foothold in regional markets. Savvy players are investing in emerging economies of Asia Pacific and Latin America that are swarming with opportunities owing to the modernization of healthcare facilities.

Q: What are the key factors driving the unfractionated heparin market?

A: The varied use of unfractionated heparin for medical care is the key driving factor of the unfractionated heparin market. Unfractionated heparin finds primary use as an anticoagulant for surgeries and for dialysis. In addition, unfractionated heparin is used for treating blood clotting disorders such as pulmonary embolism and deep vein thrombosis. Blood clotting disorders such as deep vein thrombosis have been on the rise over the past few years. Cohort studies suggest that deep vein thrombosis affects almost 900,000 individuals in the U.S. each year.

Apart from this, factors such as immediate action, simple laboratory monitoring, low cost, short half-life, and ability to reverse are also stoking the demand for unfractionated heparin. 

The rising number of geriatrics predominantly in Asia Pacific and Europe that account for a large number of cardiovascular diseases is stoking demand for unfractionated heparin as an anticoagulant. 

Q: Geographically, which region presents the most lucrative opportunities for unfractionated heparin market?

A: Driven by the vast prevalence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the U.S., North America is currently the leading market for unfractionated heparin. As much as 50% patients of DVT and PE develop secondary conditions and one-third have carry the risk of recurrence of the condition. 

Europe ranks as the second-leading market for unfractionated heparin. A large geriatric population that requires dialysis and increasing incidence of coagulation disorders are factors behind the growth of Europe unfractionated heparin market.


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports